Truong Minh T, St Clair Eric G, Donahue Bernadine R, Rush Stephen C, Miller Douglas C, Formenti Silvia C, Knopp Edmond A, Han Kerry, Golfinos John G
Department of Radiation Oncology, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
Neurosurgery. 2006 Jul;59(1):86-97; discussion 86-97. doi: 10.1227/01.NEU.0000219858.80351.38.
To determine treatment outcome after surgical resection for progressive brain metastases after gamma knife radiosurgery (GKR) and to explore the role of dynamic contrast agent-enhanced perfusion magnetic resonance imaging (MRI) and proton spectroscopic MRI studies (MRS/P) in predicting pathological findings.
Between 1997 and 2002, 32 patients underwent surgical resection for suspected progression of brain metastases from a cohort of 245 patients with brain metastases treated with GKR. Postradiosurgery MRI surveillance was performed at 6 and 12 weeks, and then every 12 weeks after GKR. In some cases, additional MRI scanning with spectroscopy or perfusion (MRS/P) was used to aid differentiation of radiation change from tumor progression. The decision to perform neurosurgical resection was based on MRI or clinical evidence of lesion progression among patients with a Karnofsky performance score of 60 or more and absent or stable systemic disease.
Thirteen percent (32 out of 245) of patients and 6% (38 out of 611) of lesions required surgical resection after GKR. The median time from GKR to surgical resection was 8.6 months (range, 1.7-27.1 mo). The 6-, 12-, and 24-month actuarial survival from time of GKR was 97, 78, and 47% for the resected patients and 65, 40, and 19% for the nonresected patients (P < 0.0001). The two-year survival rate of patients requiring two resections after GKR was 100% compared with 39% for patients undergoing one resection (P = 0.02). The median survival of resected patients was 27.2 months (range, 7.0-72.5 mo) from the diagnosis of brain metastases, 19.9 months (range, 5.0-60.7 mo) from GKR, and 8.9 months (range, 0.2-53.1 mo) from surgical resection. Tumor was found in 90% of resected specimens and necrosis alone in 10%. MRS/P studies were performed in 15 resected patients. Overall, MRS/P predicted tumor in 11 lesions, confirmed pathologically in nine lesions, and necrosis alone was found in two. The MRS/P predicted necrosis alone in three, whereas pathology revealed viable tumor in two and necrosis in one lesion.
Surgical intervention of progressive brain metastases after GKR in selected patients leads to a meaningful improvement in survival rates. Further studies are necessary to determine the role of MRS/P in the postradiosurgery surveillance of brain metastases.
确定伽玛刀放射外科治疗(GKR)后进展性脑转移瘤手术切除后的治疗效果,并探讨动态对比剂增强灌注磁共振成像(MRI)和质子磁共振波谱成像研究(MRS/P)在预测病理结果中的作用。
1997年至2002年间,32例患者因怀疑脑转移瘤进展接受了手术切除,这些患者来自245例接受GKR治疗的脑转移瘤患者队列。放射外科治疗后6周和12周进行MRI监测,之后每12周进行一次。在某些情况下,额外进行带波谱或灌注的MRI扫描(MRS/P)以辅助区分放射性改变与肿瘤进展。对于卡氏评分60分及以上且无全身疾病或全身疾病稳定的患者,决定进行神经外科切除基于MRI或病变进展的临床证据。
GKR后13%(245例中的32例)的患者和6%(611个病灶中的38个)的病灶需要手术切除。从GKR到手术切除的中位时间为8.6个月(范围1.7 - 27.1个月)。接受切除的患者从GKR开始计算的6个月、12个月和24个月精算生存率分别为97%、78%和47%,未接受切除的患者分别为65%、40%和19%(P < 0.0001)。GKR后需要两次切除的患者两年生存率为100%,而接受一次切除的患者为39%(P = 0.02)。接受切除的患者从脑转移瘤诊断开始的中位生存期为27.2个月(范围7.0 - 72.5个月),从GKR开始为19.9个月(范围5.0 - 60.7个月),从手术切除开始为8.9个月(范围0.2 - 53.1个月)。90%的切除标本中发现肿瘤,10%仅发现坏死。15例接受切除的患者进行了MRS/P研究。总体而言,MRS/P在11个病灶中预测为肿瘤,9个病灶经病理证实,2个病灶仅发现坏死。MRS/P预测3个病灶仅为坏死,而病理显示2个病灶为存活肿瘤和1个病灶为坏死。
对选定患者GKR后进展性脑转移瘤进行手术干预可显著提高生存率。需要进一步研究以确定MRS/P在脑转移瘤放射外科治疗后监测中的作用。